Reset filter
Keywords
Skitsofrenia ×
Mostra di più Keywords
Sommario
  1. 1. Test clinico
  2. 2. Documentazione di routine
  3. 3. Registro / studio di coorte
  4. 4. Garanzia di qualità
  5. 5. Dati Standard
  6. 6. Risultato segnalato dal paziente
  7. 7. Specialità mediche
    1. 7.1. Anestesiologia
    1. 7.2. Dermatologia
    1. 7.3. orecchio naso gola
    1. 7.4. Geriatria
    1. 7.5. Ginecologia / Ostetricia
    1. 7.6. Medicina Interna
      1. Ematologia
      1. Malattie infettive
      1. Cardiologia / Angiologia
      1. pneumologia
      1. Gastroenterologia
      1. Nefrologia
      1. Endocrinologia / Malattie metaboliche
      1. Reumatologia
    1. 7.7. Neurologia
    1. 7.8. Oftalmologia
    1. 7.9. Cure palliative
    1. 7.10. Patologia / Forense
    1. 7.11. Pediatria
    1. 7.12. Psichiatria / Psicosomatica
    1. 7.13. Radiologia
    1. 7.14. Chirurgia
      1. Chirurgia generale / viscerale
      1. Neurochirurgia
      1. Chirurgia plastica
      1. Chirurgia toracica
      1. Trauma / Ortopedia
      1. Chirurgia vascolare
    1. 7.15. Urologia
    1. 7.16. Medicina odontoiatrica / OMS
Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

383 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Eligibility Schizophrenia NCT00640562

- 15/10/18 - 1 modulo, 2 itemgroups, 9 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Quetiapine Extended Release Depression Symptoms; ODM derived from: https://clinicaltrials.gov/show/NCT00640562

Eligibility Schizophrenia NCT00481026

- 31/08/17 - 1 modulo, 2 itemgroups, 30 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Double Blind Sham Controlled Trial of tDCS in Treating Schizophrenia and Depression; ODM derived from: https://clinicaltrials.gov/show/NCT00481026

dbGaP phs000944 eMERGE Clinical Center at Partners HealthCare - Eligibility

- 27/11/24 - 6 moduli, 2 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: IG.elig, IG.elig
Principal Investigator: Scott T. Weiss, MD, MS, Partners HealthCare System, Boston, MA, USA MeSH: Hypercholesterolemia,Asthma,Arthritis, Rheumatoid,Attention Deficit Disorder with Hyperactivity,Bipolar Disorder,Coronary Disease,Depression,Heart Failure,Inflammatory Bowel Diseases,Multiple Sclerosis,Schizophrenia,Stroke https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000944 The Partners HealthCare Biobank is a large research data and sample repository working within the framework of Partners Personalized Medicine. It provides researchers access to high quality, consented samples to help foster research, advance understanding of the causes of common diseases, and advance the practice of medicine. The Partners Biobank provides banked samples (plasma, serum and DNA) collected from consented patients. These samples are available for distribution to Partners HealthCare investigators with appropriate approval from the Partners Institutional Review board (IRB). They are linked to clinical data that originates in the Electronic Medical Record (EMR), as well as additional health information collected in a self-reported survey. The Partners Biobank will be genotyping 25,000 subjects with the Illumina Multiethnic Beadchip 1.6 million SNPs with exome and custom content ( 60,000 LoFs). Of the participants genotyped so far, 4929 of 4962 (99.3%) individuals have genotype data that passed the default quality thresholds for the Infinium array (call rate = 0.99). We are submitting the genotype data to dbGaP for 4929 subjects with 12 phenotypes (based on icd9 codes). We will do annual releases until we reach the full 25,000 genotyped subjects.

pht004847.v1.p1

1 ItemGroup 5 elementi

pht005288.v1.p1

1 ItemGroup 6 elementi

pht004844.v1.p1

1 ItemGroup 2 elementi

pht004845.v1.p1

1 ItemGroup 3 elementi

pht004846.v1.p1

1 ItemGroup 18 elementi

dbGaP phs001020 Genomic Psychiatry Cohort (GPC) Whole Genome Sequencing and Genotyping Study - pht005781.v2.p1

- 24/08/23 - 5 moduli, 1 ItemGroup, 2 elementi, 1 linguaggio
ItemGroup: pht005781
Principal Investigator: Steven McCarroll, PhD, The Broad Institute of MIT and Harvard, Cambridge, MA, USA MeSH: Schizophrenia,Bipolar Disorder https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001020 The Center for Genomic Psychiatry at the University of Southern California (USC), SUNY Downstate and an extensive network of academic medical centers have created the Genomic Psychiatry Cohort (GPC). The GPC consists of a large clinical cohort of patients with schizophrenia, bipolar disorder, and healthy controls. The data generation of genotyping and whole genome sequencing of the GPC has been done in collaboration with the USC and the Broad Institute of MIT and Harvard. Genome-wide association studies are being performed with the samples to identify genetic risks for psychiatric disease. Genotyping is also being used to determine ancestry informative markers and replication of candidate genes. Whole genome sequencing identifies functional variants associated with disease risk.

pht005782.v2.p1

1 ItemGroup 2 elementi

pht005783.v2.p1

1 ItemGroup 5 elementi

pht005784.v2.p1

1 ItemGroup 7 elementi

Eligibility

1 ItemGroup 1 elemento

Eligibility Schizophrenic Disorders NCT00161408

- 14/02/16 - 1 modulo, 2 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Psychological Intervention for Relapse Prevention in First Episode Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00161408

Eligibility Schizophrenia NCT01810783

- 24/11/20 - 1 modulo, 2 itemgroups, 8 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Brexpiprazole in Patients With Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT01810783 according to the information on www.clinicaltrials.gov other inclusion and exclusion criteria may apply.

dbGaP phs000979 HBCC Postmortem Psychiatric Molecular Studies - pht005195.v2.p2

- 17/01/24 - 5 moduli, 1 ItemGroup, 20 elementi, 1 linguaggio
ItemGroup: pht005195
Principal Investigator: Barbara K. Lipska, PhD, National Institutes of Health, Bethesda, MD, USA MeSH: Schizophrenia,Anxiety Disorders,Autism Spectrum Disorder,Bipolar Disorder,Control Groups,Feeding and Eating Disorders,Depressive Disorder, Major,Obsessive-Compulsive Disorder,Stress Disorders, Post-Traumatic,Tic Disorders,Williams Syndrome https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000979 This postmortem study examines molecular, genetic and epigenetic signatures in the brains of hundreds of subjects with or without mental disorders conducted by the DIRP NIMH Human Brain Collection Core (HBCC). The brain tissues are obtained under protocols approved by the CNS IRB (NCT00001260), with the permission of the next-of-kin (NOK) through the Offices of the Chief Medical Examiners (MEOs) in the District of Columbia, Northern Virginia and Central Virginia. Additional samples were obtained from the University of Maryland Brain and Tissue Bank (contracts NO1-HD-4-3368 and NO1-HD-4-3383) (http://www.medschool.umaryland.edu/btbank/ and the Stanley Medical Research Institute (http://www.stanleyresearch.org/brain-research/). Clinical characterization, neuropathological screening, toxicological analyses, and dissections of various brain regions were performed as previously described (Lipska et al. 2006; PMID: 16997002). All patients met DSM-IV criteria for a lifetime Axis I diagnosis of psychiatric disorders including schizophrenia or schizoaffective disorder, bipolar disorder and major depression. Controls had no history of psychiatric diagnoses or addictions. *SNP array:* Array-based genotyping was performed on most samples published in this collection. The number of SNPs assayed via Illumina chips varied between 650,000 and 5 Million. Cerebellar tissue was generally used for genotyping studies. table width="481" border="1" tbody tr td width="64" align="center" strong#/strong /td td width="275" strongDiagnosis/strong /td td width="57" align="center" strongSNP Array/strong /td /tr tr td width="64" align="center"1/td td width="275"Anxiety Disorder/td td width="57" align="center"1/td /tr tr td width="64" align="center"2/td td width="275"Autism Spectrum Disorder/td td width="57" align="center"13/td /tr tr td width="64" align="center"3/td td width="275"Bipolar Disorder/td td width="57" align="center"114/td /tr tr td width="64" align="center"4/td td width="275"Control/td td width="57" align="center"387/td /tr tr td width="64" align="center"5/td td width="275"Eating Disorder (ED)/td td width="57" align="center"2/td /tr tr td width="64" align="center"6/td td width="275"Major Depressive Disorder (MDD)/td td width="57" align="center"186/td /tr tr td width="64" align="center"7/td td width="275"Obsessive Compulsive Disorder (OCD)/td td width="57" align="center"5/td /tr tr td width="64" align="center"8/td td width="275"Post-Traumatic Stress Disorder (PTSD)/td td width="57" align="center"0/td /tr tr td width="64" align="center"9/td td width="275"Schizophrenia/td td width="57" align="center"220/td /tr tr td width="64" align="center"10/td td width="275"Other/td td width="57" align="center"7/td /tr tr td width="64" align="center"11/td td width="275"Tic Disorder/td td width="57" align="center"3/td /tr tr td width="64" align="center"12/td td width="275"Undetermined/td td width="57" align="center"1/td /tr tr td width="64" align="center"13/td td width="275"Williams Syndrome/td td width="57" align="center"2/td /tr /tbody /table Table: *Numbers of samples in each diagnostic category*. DNA extraction: 45-80 mg of cerebellar tissue was pulverized for DNA extractions. The QIAamp DNA mini Kit (Qiagen) method was employed for tissue DNA extraction. The tissue was initially lysed using Tissue Lyser (Qiagen) and extractions were accomplished according to manufacturer's protocol. The DNA was captured in 500uL elution buffer. The concentrations were measured using Thermo Scientific's NanoDrop 1000/NanoDrop ONE. The mean yield was 128.85 uG (+/- 79.48), the mean ratio of 260/280 was 1.87 (+/- 0.105), and the mean ratio of 260/230 was 2.48 (+/-1.75). Genotyping methods: Three types of Illumina Beadarray chips were used: HumanHap650Y, Human1M-Duo, and HumanOmni5M-Quad (San Diego, California). The genotyping was done according to the manufacturer's protocol (Illumina Proprietary, Catalog # WG-901-5003, Part # 15025910 Rev.A, June 2011). Approximately, 400ng DNA was used and each DNA sample was QC tested for 260/280 ratio by nanodrop and DNA band intactness on 2% agarose gel. Briefly, the samples were whole-genome amplified, fragmented, precipitated and resuspended in appropriate hybridization buffer. Denatured samples were hybridized on prepared Bead Array Chips. After hybridization, the Bead Chip oligonucleotides were extended by a single fluorescent labeled base, which was detected by fluorescence imaging with an Illumina Bead Array Reader, iScan. Normalized bead intensity data obtained for each sample were loaded into the Illumina Genome Studio (Illumina, v.2.0.3) with cluster position files provided by Illumina, and fluorescence intensities were converted into SNP genotypes. *Microarray:* We generated RNA expression data using array technology for psychiatric subjects compared to non-psychiatric subjects as controls. We used tissues from three different brain regions i.e. hippocampus, dorsolateral prefrontal cortex (DLPFC), and dura mater for a large cohort of individuals (total number 552 subjects for hippocampus, 800 for DLPFC and 146 for dura). Total RNA was extracted from ~100 mg of tissue using the RNeasy kit (Qiagen) according to the manufacturer's protocol. RNA quality and quantity were examined using the Bioanalyzer (Agilent, Inc) and NanoDrop (Thermo Scientific, Inc), respectively. Samples with RNA integrity number (RIN) 5 were excluded. Affymetrix 3'IVT express kit protocols (Affymetrix, Inc. catalog#902416) were used to generate the Biotin labeled cRNAs. The Illumina hybridization cocktail containing 2 micrograms of biotin labeled cRNAs was hybridized to the Illumina HumanHT-12_V4 Beadchips. The chips were washed and stained using the standard Illumina protocols and reagents. The Illumina BeadChip Scanner was used to scan the arrays. Gene expression intensities were extracted using the Illumina GenomeStudioV2011.1 software. table width="481" border="1" tbody tr td width="64" align="center" strong#/strong /td td width="275" strongDiagnosis/strong /td td width="57" align="center" strongDLPFC/strong /td td width="47" align="center" strongHippo/strong /td td width="39" align="center" strongDura/strong /td /tr tr td width="64" align="center"1/td td width="275"Anxiety Disorder/td td width="57" align="center"1/td td width="47" align="center"0/td td width="39" align="center"0/td /tr tr td width="64" align="center"2/td td width="275"Autism Spectrum Disorder/td td width="57" align="center"14/td td width="47" align="center"6/td td width="39" align="center"0/td /tr tr td width="64" align="center"3/td td width="275"Bipolar Disorder/td td width="57" align="center"90/td td width="47" align="center"49/td td width="39" align="center"0/td /tr tr td width="64" align="center"4/td td width="275"Control/td td width="57" align="center"336/td td width="47" align="center"270/td td width="39" align="center"75/td /tr tr td width="64" align="center"5/td td width="275"Eating Disorder (ED)/td td width="57" align="center"2/td td width="47" align="center"1/td td width="39" align="center"0/td /tr tr td width="64" align="center"6/td td width="275"Major Depressive Disorder (MDD)/td td width="57" align="center"144/td td width="47" align="center"87/td td width="39" align="center"0/td /tr tr td width="64" align="center"7/td td width="275"Obsessive Compulsive Disorder (OCD)/td td width="57" align="center"5/td td width="47" align="center"3/td td width="39" align="center"0/td /tr tr td width="64" align="center"8/td td width="275"Post-Traumatic Stress Disorder (PTSD)/td td width="57" align="center"6/td td width="47" align="center"0/td td width="39" align="center"0/td /tr tr td width="64" align="center"9/td td width="275"Schizophrenia/td td width="57" align="center"192/td td width="47" align="center"125/td td width="39" align="center"71/td /tr tr td width="64" align="center"10/td td width="275"Other/td td width="57" align="center"5/td td width="47" align="center"6/td td width="39" align="center"0/td /tr tr td width="64" align="center"11/td td width="275"Tic Disorder/td td width="57" align="center"3/td td width="47" align="center"3/td td width="39" align="center"0/td /tr tr td width="64" align="center"12/td td width="275"Undetermined/td td width="57" align="center"1/td td width="47" align="center"1/td td width="39" align="center"0/td /tr tr td width="64" align="center"13/td td width="275"Williams Syndrome/td td width="57" align="center"2/td td width="47" align="center"1/td td width="39" align="center"0/td /tr /tbody /table Table: *Numbers of samples in each diagnostic category*. *RNA-Seq of Dorso-lateral prefrontal cortex:* All brains were collected and the dorsolateral prefrontal cortical (DLPFC) samples dissected at the HBCC, DIRP, NIMH. Dorsolateral prefrontal cortex (DLPFC) specimens were dissected from right or left hemisphere of frozen coronal slabs. The study was funded by the DIRP, NIMH under contract (#HHSN 271201400099C) with Icahn School of Medicine at Mount Sinai,1106402 One Gustave L. Levy Place, Box 3500, New York NY 10029,6574. RNA extraction, library preparation and sequencing were performed under contract at Icahn School of Medicine. The Common Mind Consortium (CMC) provided project management support. RNA isolation: Total RNA from 468 HBCC samples was isolated from approximately 100 mg homogenized tissue from each sample by TRIzol/chloroform extraction and purification with the Qiagen RNeasy kit (Cat#74106) according to manufacturer's protocol. Samples were processed in randomized batches of 12. The order of extraction for schizophrenia, bipolar, and MDD disorders and control samples was assigned randomly with respect to diagnosis and all other sample characteristics. The mean total RNA yield was 24.2 ug (+/- 9.0). The RNA Integrity Number (RIN) was determined by 4200 Agilent TapeStation System. Samples with RIN 5.5 were excluded from the study. Among the remaining samples the mean RIN was 7.5 (+/- 0.9) and the mean ratio of 260/280 was 2.0 (+/- 0.03). DLPFC RNA-Seq quantified expression data are provided for 364 samples. Data were generated, QC'd, processed and quantified as follows: RNA library preparation and sequencing: All samples submitted to the New York Genome Center for RNAseq were prepared for sequencing in randomized batches of 94. The sequencing libraries were prepared using the KAPA Stranded RNAseq Kit with RiboErase (KAPA Biosystems). rRNA was depleted from 1ug of RNA using the KAPA RiboErase protocol that is integrated into the KAPA Stranded RNAseq Kit. The insert size and DNA concentration of the sequencing library was determined on Fragment Analyzer Automated CE System (Advanced Analytical) and Quant-iT PicoGreen (ThermoFisher) respectively. table width="317" border="1" tbody tr td width="104" align="center" strongSchizophrenia/strong /td td width="67" align="center" strongBipolar/strong /td td width="68" align="center" strongControl/strong /td /tr tr td align="center"89/td td align="center"65/td td align="center"210/td /tr /tbody /table Table: *Numbers of samples in each diagnostic category*. *RNA-Seq of subgenual anterior cingulate cortex (sgACC):* All the 200 post-mortem brain samples (61 controls; 39 bipolar disorder; 46 schizophrenia; 54 major depressive disorder) were collected by the HBCC, DIRP, NIMH. RNA Extraction and Quality Assessment: Tissue from sgACC was pulverized and stored at -80°C. Total RNA was extracted from 50-80 mg of the tissue using QIAGEN RNeasy Lipid Tissue Mini Kit (QIAGEN, Cat. # 74804) with DNase treatment (QIAGEN, Cat. # 79254). The RNA Integrity Number (RIN) for each sample was assessed with high-resolution capillary electrophoresis on the Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, California). The concentration of RNA and their 260/280 ratio (2.1+/- 0.032 SD) were determined with NanoDrop (Thermo Scientific). RNA sequencing: Stranded RNA-Seq libraries were constructed after rRNA depletion using Ribo-Zero GOLD (Illumina). RNA sequencing was performed at National Institute of Health Intramural Sequencing Center (NISC). table width="317" border="1" tbody tr td width="104" align="center" strongSchizophrenia/strong /td td width="67" align="center" strongBipolar/strong /td td width="68" align="center" strongControl/strong /td td width="78" align="center" strongMDD/strong /td /tr tr td align="center"46/td td align="center"39/td td align="center"61/td td align="center"54/td /tr /tbody /table Table: *Numbers of samples in each diagnostic category*. *Whole Genome Sequencing:* All brains were collected and dissected at the HBCC, DIRP, NIMH. This study generates whole genome sequencing data using sequencing of DNA in the dorsolateral prefrontal cortex (DLPFC), anterior cingulate cortex (ACC) or cerebellum of 443 individuals with schizophrenia, bipolar disorder and major depressive disorder and non-psychiatric controls. The study was funded by the DIRP, NIMH under contract (#HHSN 271201400099C) with Icahn School of Medicine at Mount Sinai,1106402 One Gustave L. Levy Place, Box 3500, New York NY 10029,6574. DNA extraction, library preparation and sequencing were performed under contract at Icahn School of Medicine. The Common Mind Consortium (CMC) provided project management support. All specimens were dissected from right or left hemisphere of frozen coronal slabs. DNA Library Preparation and Sequencing: All samples submitted to the New York Genome Center for WGS were prepared for sequencing in randomized batches of 95. The sequencing libraries were prepared using the Illumina PCR-free DNA sample preparation Kit. The insert size and DNA concentration of the sequencing library was determined on Fragment Analyzer Automated CE System (Advanced Analytical) and Quant-iT PicoGreen (ThermoFisher) respectively. A quantitative PCR assay (KAPA), with primers specific to the adapter sequence, was used to determine the yield and efficiency of the adaptor ligation process. Performed on the Illumina HiSeqX with 30X coverage. table width="233" border="1" tbody tr td width="99" align="center" strongSchizophrenia/strong /td td width="67" align="center" strongBipolar/strong /td td width="68" align="center" strongControl/strong /td /tr tr td align="center" strong115/strong /td td align="center"78/td td align="center"230/td /tr /tbody /table Table: *Numbers of samples in each diagnostic category*. *ChIP-Seq:* All brains were collected and the dorsolateral prefrontal cortical (DLPFC) samples dissected at the HBCC, DIRP, NIMH. This study generates epigenetic data using sequencing of DNA after chromatin immunoprecipitation (ChIP-Seq) for marks H3K4me3 and H3K27ac in the dorsolateral prefrontal cortex (DLPFC). Dorsolateral prefrontal cortex (DLPFC) specimens were dissected from right or left hemisphere of frozen coronal slabs. The study was funded by the DIRP, NIMH under contract (#HHSN 271201400099C) with Icahn School of Medicine at Mount Sinai,1106402 One Gustave L. Levy Place, Box 3500, New York NY 10029,6574. Chromatin precipitation, library preparation and sequencing were performed under contract at Icahn School of Medicine. The Common Mind Consortium (CMC) provided project management support. Chromatin immunoprecipitation (ChIP) assays for histone marks H3K4me3 and H3K27ac were carried out using Native ChIP. Micrococcal Nuclease (MNase) (Sigma, N3755) treatment was used to digest chromatin into mononucleosomes. The following antibodies were used for chromatin pull-down: anti-H3K4me3 (Cell Signaling, Cat# 9751BC, lot 7) and anti-H3K27ac (Active Motif, Cat# 39133, Lot # 31814008). Histone modification-enriched genomic DNA fragments were recovered using Protein A/G magnetic beads (Thermo Scientific, 88803-88938 or Millipore 16-663), and then washed, eluted, and treated with RNAse A and proteinase K. Final ChIP DNA products were isolated using phenol-chloroform extraction followed by ethanol precipitation. The efficiency of each ChIP assay was validated using Qubit concentration measurement and qPCR for positive (GRIN2B, DARPP32) and negative (HBB) control genomic regions. Only ChIP assays that passed quality control were further processed for library preparation and sequencing; this included ChIP DNA that was not detectable on Qubit but showed a good signal and expected enrichment patterns in qPCR. table width="291" border="1" tbody tr td width="64" align="center" strong/strong /td td colspan="3" width="153" align="center" strongHISTONE_MARK/strong /td td width="73" align="center" strong/strong /td /tr tr td width="64" align="center" /td td colspan="2" width="77" align="center" strongH3K27ac/strong /td td width="77" align="center" strongH3K4me3/strong /td td width="73" align="center" strongInput/strong /td /tr tr td width="64" strongBipolar/strong /td td width="73" align="center"56/td td colspan="2" width="80" align="center"4/td td width="73" align="center" strong7/strong /td /tr tr td width="64" strongControl/strong /td td width="73" align="center"158/td td colspan="2" width="80" align="center"11/td td width="73" align="center"24/td /tr tr td width="64" strongSchizophrenia/strong /td td width="73" align="center"79/td td colspan="2" width="80" align="center"11/td td width="73" align="center"12/td /tr /tbody /table Table: *Numbers of individuals in each assay grouped by histone mark or input*.

Eligibility

1 ItemGroup 2 elementi

pht005196.v3.p2

1 ItemGroup 7 elementi

pht005193.v2.p2

1 ItemGroup 2 elementi

pht005194.v3.p2

1 ItemGroup 2 elementi

dbGaP phs000682 Genetics of Neuropsychiatric and Neurodevelopmental Disorders - Eligibility

- 24/01/23 - 6 moduli, 1 ItemGroup, 15 elementi, 1 linguaggio
ItemGroup: IG.elig
Principal Investigator: David Goldstein, PhD, Duke University, Durham, NC, USA MeSH: Schizophrenia,Schizoaffective disorder,Attention Deficit Hyperactivity Disorder,Seizures,Oppositional defiant disorder,Anxiety,Depression,Autism,Autism Spectrum Disorders,Bipolar Disorder,Developmental Disabilities,Ataxia,Migraine,Paranoid schizophrenia,Obsessive compulsive disorder,Kluver-Bucy syndrome,Intellectual disability https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000682 Although schizophrenia is a highly heritable disease, relatively little progress had been made in securely identifying the genetic causes of this disorder, and most instances of schizophrenia in the general population remain unexplained. One avenue of explanation for the genetic basis of schizophrenia, however, has been effectively closed by recent research. Genome-wide association studies (GWAS) have now shown that common variation makes at most a modest contribution to the risk of schizophrenia. At the same time that the role of common variation has been circumscribed by GWAS, however, the analysis of copy number variants that are detectable on a genome-wide scale has revealed and replicated a number of very rare variants that associate with schizophrenia. These rare copy number variants that have been implicated in schizophrenia, however, have one striking feature in common: they are all risk factors for other brain related disorders beyond schizophrenia such as mental retardation, autism and epilepsy. These findings argue that genetic risk factors may confer a highly penetrant vulnerability to neuropsychiatric disorder, which is then further modified by interacting genetic or environmental factors to determine the ultimate manifestation. Most schizophrenia collections that are being studied today, however, have been selected precisely for their homogeneity: including only schizophrenia patients with no comorbidities, or schizophrenia patients with relatives who have schizophrenia but no other neuropsychiatric conditions. These selection criteria are inconsistent with what we now know about the bulk of the genetic differences that have been associated with disease. The central hypothesis of this project is that there are rare genetic variants that strongly elevate the risk of various neuropsychiatric diseases, and that these risk factors can be identified most readily in families segregating multiple neuropsychiatric conditions.

pht003594.v1.p1

1 ItemGroup 5 elementi

pht003595.v1.p1

1 ItemGroup 6 elementi

pht003596.v1.p1

1 ItemGroup 5 elementi

pht003597.v1.p1

1 ItemGroup 5 elementi

pht003598.v1.p1

1 ItemGroup 3 elementi

Eligibility Schizophrenia and Disorders With Psychotic Features NCT00791882

- 28/09/21 - 1 modulo, 2 itemgroups, 19 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Social Skills Training in Refractory Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00791882

Eligibility Schizophrenia NCT00654706

- 20/09/21 - 1 modulo, 2 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00654706

Eligibility Schizophrenia NCT01165294

- 20/09/21 - 1 modulo, 2 itemgroups, 16 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
The Effect of Ketamine on Attentiveness; ODM derived from: https://clinicaltrials.gov/show/NCT01165294

Eligibility Schizophrenia NCT00791193

- 20/09/21 - 1 modulo, 2 itemgroups, 13 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR; ODM derived from: https://clinicaltrials.gov/show/NCT00791193

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial